Publications

Psoriasis

Relevant publications

Augustin, M. et al. A New Landmark for Wellbeing in Psoriasis: The POSITIVE Study EMJ Dermatol. 2023;11[1]:71-78. DOI/10.33590/emjdermatol/ 10308846.

View

Narcisi, A. et al. Real-­ life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-­ week multicentre retrospective study—­ IL PSO (Italian landscape psoriasis) DOI: 10.1111/jdv.18594

View

Costanzo, A. et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-­ to-­ severe plaque psoriasis patients in conditions close to clinical practice. DOI: 10.1111/jdv.19229

View

Augustin, M. et al. Patient-­reported well-­being in value-based care using tildrakizumab in a real-­world setting: protocol of a multinational, phase IV, 1-­cohort prospective observational study (the POSITIVE study). DOI: 10.1136/bmjopen-2021-060536

View

Egeberg, A. et al. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. https://doi.org/10.1080/09546634.2023.2220447

View

Gebauer, K. et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. https://doi.org/10.1016/j.jaad.2024.03.025

View

Lebwohl, M.G. et al. Biologics for the Treatment of Moderate‑to‑Severe Plaque Psoriasis: A Systematic Review and Network Meta‑analysis https://doi.org/10.1007/s13555-025-01357-7

View

Ständer, S. et al. Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. https://doi.org/10.1080/09546634.2024.2438803

View

Thaci, D. et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). DOI: 10.1111/bjd.19866

View

Welcome to almiralldermatologycongress.com

The information provided on this website is intended for use by healthcare professionals qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

I'm not a Healthcare Professional

I'm a Healthcare Professional

Leaving almiralldermatologycongress.com

Dear User,

You are about to leave almiralldermatologycongress.com since your request does not correspond to Almirall’s content related to EADV Congress 2024.

We will redirect you to almirall.com

Thanks for your visit.

Come back soon!

Leave

Return

Prof. Dirschka

Germany

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Thomas Dirschka graduated in medicine at the University of Bochum, Germany in 1993 and has since specialised in dermatology. After a period of research at the Medical College of Virginia in the USA, Professor Dirschka returned to Germany and did further research work before entering private dermatological practice.

His areas of special interest include prevention and treatment of skin cancer, inflammatory skin diseases, allergy,dermatopathology, and aesthetic dermatology.

He is actively involved in clinical study programmes and clinical trials to determine the efficacy and safety of novel treatments for dermatological conditions. In 2000 Professor Dirschka founded CentroDerm®, a company for research and development in the field of dermatology. In this context he runs a skin physiology laboratory for investigation of skin barrier function, skin sensitivity and effects of topical applications on the skin.

Prof. Fargnoli

Italy

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Maria Concetta Fargnoli is Full Professor of Dermatology and Chair of the Department of Dermatology at the University of L’Aquila, Italy. She received her medical degree in 1992 at the University of Rome “Tor Vergata”, completed her residency in Dermatology and Venereology at the University of L’Aquila in 1998 and started her academic career in 1999. She is the Director of the Laboratory of Molecular Biology in Dermato-Oncology, Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, Faculty of the PhD Program in Experimental Medicine at the University of L’Aquila and Coordinator of the Skin Cancer Tumor Board.

Her clinical and experimental research interests include epidemiology and molecular genetics of melanoma and non-melanoma skin cancers, non-invasive diagnostic techniques in dermatology, new therapeutic interventions for inflammatory and neoplastic skin diseases. She is actively involved in conducting clinical trials primarily focusing on non-melanoma skin cancers, psoriasis, atopic dermatitis and prurigo nodularis.

She has published 265 peer-reviewed scientific papers, contributed to many book chapters and lectured at national and international meetings. Prof. Fargnoli acts as reviewer of international journals on dermatology, oncology and genetics.

Prof. Fargnoli is currently VicePresident of the Italian Society of Dermatology (SIDeMaST) and has been board member, secretary, coordinator of the Group of Experimental Research and Bioengeneering in Dermatology and coordinator of the Scientific Committee of SIDeMaST.

Dr. Boada

Spain

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Dr. Aram Boada (Barcelona, 1979) is a specialist in Dermatology and Venereology (2008) and PhD degree from the Universitat Autònoma de Barcelona (2020). He works as Section Chief and Melanoma Unit Coordinator of the Dermatology Department of Hospital Universitari Germans Trias i Pujol in Badalona (Barcelona, Spain). His main fields of research are Dermato-Oncology (melanoma, field cancerization and cutaneous toxicities of oncologic treatments) with more than 100 publications and conference communications.